The effects of transfer day in intracytoplasmic sperm injection (ICSI) pregnancies on first trimester screening test results

Nur Dokuzeylül Güngör¹, Tuğba Gürbüz², Aynur Erşahin¹
¹Department of IVF Center, Medical Park Göztepe Hosp., İst./ Turkey
²Department of Gynecology and Obstetric, Medical Park Göztepe Hosp., İst./ Turkey

ABSTRACT

Objects: To compare first trimester screening (FTS) serum markers free β-human chorionic gonadotropin (free β-hCG) and pregnancy associated plasma protein A (PAPP-A) of blastocyst versus cleavage stage embryo transfers after assisted reproductive technologies (ART).

Methods: Retrospective examinations of 123 women who conceived with ART were subjected to FTS from January 2017 to December 2017 at Bahçeşehir University Göztepe Medical Park Hospital In Vitro Fertilization (IVF) Unit. The age, gestational week, ultrasound (US) markers and biochemistry markers (PAPP-A, free β-hCG) were collected. Outcomes were regarded as meaningful when the p < 0.05. Statistical Package For Social Sciences (SPSS) v.17.0 for Windows was preferred to make statistical analysis.

Results: PAPP-A amounts were remarkably low in day-3 (cleavage stage embryos) transfer intracytoplasmic sperm injection (ICSI) pregnancies compared to day-5 (blastocyst stage embryos) transfer ICSI pregnancies. Free β-hCG amounts weren’t significantly different in two groups (p=0.371). NT was unaffected by the transferenceday (p=0.21). Also CRL was unaffected by the transferenceday (p=0.693). No differences appeared between 3rd and 5th day embryo transference according to maternal age (p=0.616), weight (p=0.693) and gestational age (p=0.742) at sampling.

Conclusion: Today, the datas about the effects of ART over the ingredients of combined FTS for chromosomal analysis are contentious yet. Day-3 ICSI pregnancies had meaningfully low PAPP-A amounts which support the requirement to properly set the combined FTS risks algorithm. These outcomes are likely to be because of changings in the placenta of ART pregnancies.

Keywords: Assisted reproduction techniques, blastocyst, cleavage, first trimester screening
İlk trimester tarama testi sonuçlarında transfer gününün intrasitoplazmik sperm enjeksiyonu (ICSI) gebeliklerindeki etkileri

ÖZET

Amaç: Blastosist ve klivaj aşaması embriyo transferleri arasında ilk trimester taramasındaki serum belirteçleri olan serbest β- koryonik gonodotropini (serbest β-hCG) ve plazma ilişkili A proteinini (PAPP-A), karşılaştırmak.

Yöntem: Ocak 2017-Aralık 2017 tarihleri arasında Bahçeşehir Üniversitesi Göztepe Medical Park Hastanesi IVF Ünitesi'nde ART ile gebe olan 123 kadının retrospektif ilk trimester tarama testi sonuçları tarandı. Yaş, gebelik haftası, ultrason belirteçleri ve biyokimya belirteçleri (PAPP-A, serbest β-hCG) toplanı. Sonuçlar p< 0.05 olduğunda anlamlı görüldü. İstatistiki analiz için Sosyal Bilimler için İstatistik Paketi (SPSS) 17.0 sürüümü Windows kullanıldı.

Bulgular: PAPP-A düzeyleri klivaj gebeliklerinde blastosist gebeliklerine kıyaslaoldukça düştü (p <0.05). Serbest β-hCG seviyeleri iki grupta anımlı olarak farklılık göstermedi (p = 0.371). NT transfer gününden etkilenmedi (p = 0.21). Ayrıca CRL, transfer gününden etkilenmedi (p = 0.693). Örneklemede anne yaşısı, (p = 0.616) ağırlık (p = 0.693) ve gebelik yaşına (p = 0.742) göre 3. ve 5. gün embriyo transferi arasında fark saptanmadı.

Sonuç: Günümüzde, ART'ın birinci trimester kombine taramanın bileşenleri üzerindeki etkisi üzerine veriler hala tartışmalıdır. Klivaj ICSI gebeliklerinde anımlı düzeyde düşük PAPP-A seviyeleri ART gebeliklerinin plasentasyonundaki değişikliklere bağlı olabilmektedir.

Anahtar kelimeler: Yardımcı üreme teknikleri, blastosist, klivaj, ilk trimester taraması
INTRODUCTION

The blastocyst transferences established on an advanced culture structure have been proven efficient to select embryos, which results in an increased implantation ratio besides not effecting pregnancy ratio (1). Increased implantation ratios can let less-transferring but more-qualified embryos at the blastocyst phase, in this way it can be ensured to avoid from multiple pregnancy incidences (2). Time extension of embryo culture to the blastocyst phase for ART presents a number of theoretic benefits for the transference of cleavage-phase embryos. Some of the benefits are: 1) decreasing embryos' being exposed to hyper-induced uterine circumference to minimum level, 2) providing a rather good physiologic synchronicity between embryo layer and the endometrium during embryos transference (3), 3) making the most effective and optimized election of embryos which have the higher implantation capacity, 4) boosting the probability to went through cryopreservation, and 5) decreasing uterine spasms, etc. Nevertheless, there is some particular disadvantages in blastocyst phase. By use of todays methods, several cleavage embryos can't evolve into blastocysts in vitro and cryopreservation of several blastocysts can't be ensured in good way. Hence, there is questions yet over if the transference of blastocyst-phase embryos is useful to entire patients who is not fertile (4-8).

FTS unites the mother age connected risks with the measurements of biochemical markers (free β-hCG and PAPP-A) and fetal nuchal translucency (NT) to estimate Down Syndrome (DS) (trisomy21), Edwards Syndrome (ES) (trisomy18) and Patau Syndrome (PS) (trisomy13) risks.

This test uses the motherhood blood amounts of free β-hCG and PAPP-A and the measurements of the NT and crown rump length (CRL) by US method in the period of 11+3rd and 13+6th weeks pregnancy (9). The motherhood serum amounts of PAPP-A and free
β-hCG are stated as multiples of the median (MoM). DS threat increases if the rate of the free β-hCG MoM to PAPP-A MoM increases, however reduced amounts of each markers are related with a higher threat for ES and PS.

The combine FTS has 95 percent perception ratio for DS (9), with 5 percent monitor-positive ratio (10). An increased threat, or monitor-positive combine FTS outcome shows that the defined danger based on the US and biochemistry is higher than 1 in 300. Plenty of monitor-positives are not affected from aneuploidy, for this reason they may be incorrect-positives (9).

The perception ratio can be made higher up to 95 percent, decreasing the incorrect-positive ratio to lesser than 3 percent with the inclusion of extra US markers (nasal bone, ductus venosus or tricuspid Doppler) (11,12). The scanning test elements must be set by use of several factors which can change US or biochemical markers for improving it's correctness. Some of the factors are: pregnancy and motherhood features such as pregnancy age, mother weight, ethnicity, smoke dependence, diabetes mellitus and pregnancy way (11-15).

Today, 1 to 4 percent of infants born in entire advanced countries became pregnant thanks to ART (16,17).

**Material and Methods**

This retrospective research was confirmed within the Ethics Commitee of Göztepe Medicalpark Hosp., Istanbul, Turkey (2017/13019). 123 singleton pregnancies (SP) conceived by ART, who admitted combine FTS of DS from January 2017 to December 2017 in IVF center.

FTS was applied after the Fetal Medicine Foundation (FMF) principles at 11+0 to 13+6th week of pregnancy, subsequently acquiring inscribed permission. The US survey and the
motherhood blood collection for the biochemical test were fulfilled on the same date. Merely SP were comprised in the research. Exception criterions were multiple pregnancies, SP consequence of embryo declining (inherent or stimulated), and pregnancies with structural fetal disabilities or any chromosomal deformities. Fresh embryos were included. The calculated marker grades were stated as MoM for pregnancy age after setting for mother weight.

Statistical analysis

SPSS v.17.0 for Windows was preferred to make statistical analysis. The Shapiro-Wilk testing was preferred to determine the accuracy of data regulation. Meaning of differentiations of each group was defined with the use of the unparametric Mann–Whitney U-testing. Differentiations in serum levels and fetal NT were evaluated with the Kruskal–Wallis testing. Meaning was accepted at p<0.05.

Results

First chart summarizes motherhood features and pregnancy age at case exemplifications. No differences appeared between 3rd and 5th day embryo transference according to motherhood age (p=0.616) and weight (p=0.693). It wasn't seen any differentiation of pregnancy age in exemplification in both groups. (p=0.742). Chart 2 shows ultrasound markers and biochemistry markers of the cases. However, day-3 transfer patients presented meaningfully low PAPP-A MoM datas than day 5 transfer patients (p=0.031). There weren’t significant differentiation of free β-hCG amounts in both groups (p=0.371). NT was unaffected by the transference day (p=0.21). Also CRL was unaffected by the transference day (p=0.693).
Chart 1 motherhood features and pregnancy age at case exemplifications

| Parameters                                    | Cleavage stage n=40 | Blastocyst n=83 | P value |
|-----------------------------------------------|---------------------|-----------------|---------|
| Motherhood age                                | 32,6±4,09           | 32,18±4,44      | 0.616   |
| Average±std.deviation                         |                     |                 |         |
| Motherhood weight in exemplification (kg)     | 64,90±10,82         | 65,19±12,82     | 0.693   |
| Average±std.deviation                         |                     |                 |         |
| Pregnancy age in exemplification (week)       | 12,2±0,67           | 12,32±0,64      | 0.742   |
| Average±std.deviation                         |                     |                 |         |

Chart 2: Ultrasound markers and biochemistry markers of the cases

| Parameters                                    | Cleavage stage n=40 | Blastocyst n=83 | P value |
|-----------------------------------------------|---------------------|-----------------|---------|
| Free B-hCG levels (IU/L) median±std.deviation| 41,19±28,91         | 48,33±34,51     | 0.371   |
| PAPP-A levels(IU/L) median±std.deviation     | 3,06±2,02           | 3,92±2,94       | 0.031   |
| NT median±std.deviation                      | 1,55±0,35           | 1,47±0,37       | 0.21    |
| CRL median±std.deviation                     | 58,06±7,43          | 58,75±7,96      | 0.693   |

Discussion

Serum proteins are synthetized by placenta (PAPP-A, free β-hCG, hCG and unconjugated estriol (uE3) and by the fetus (alpha fetoprotein (AFP)). Motherhood serum amount of AFP in second trimester (ST) is produced by malformed alteration of the fetal liver in DS embryos.
(18), the alterations in the amounts of placenta-provided proteins weren't took into account. Recent researches have shown that the synthetis of placenta-produced proteins in DS and normal placentae has differences from cyto- to syncytiotrophoblast that is disrupted in DS placenta, pursued by a changing of the synthetis of placenta-produced proteins (19). The free β-hCG has been described as the preferable calculation value in scanning DS, in spite of the fact that it has not been verified in any researches which have been carried out till today (20,21 ). Free β-hCG is necessary for the maintaining of pregnancy. This serum marker first gets higher till 10th week of pregnancy and after gets lower toward term (22,23). In FT of pregnancy, increased amounts of free β-hCG are related to DS, and in the ST related to bad obstetric result (24,25,26). The differentiation between the two amounts of β-hCG is related to the effects of unfavorable pregnancies and advancing GA (26).

The amount of free β-hCG is low when FT IVF is compared with usual pregnancy (27), whereas in the ST free β-hCG is high in IVF pregnancy (28-30).

The low amount of PAPP-A observed in DS pregnancy indicates a common crisis of the insulin-like development component axis in DS pregnancy (31,32). Because IGFs are included in trophoblast incursion, alterations in the bioavailability of these hormones may be associated with the higher ratio of pregnancy problems depended on DS pregnancy. Low motherhood serum amounts of PAPP-A in DS pregnancy is not particular, because diminished amounts of PAPP-A are observed in pregnancies of pre-eclampsia and intrauterine growing delay (18,19).

Form of impregnation, culture environment and cultural circumstances are different ways to treat fertility that may have an effect on the embryos, implantation and untimely pregnancies (33). Low PAPP-A has been notified without looking if the reason of being infertile was because of the male, female, or both. The pathophysiological ground for this decrease in
PAPP-A amounts following conceived pregnancies with assistance could still not found out. Problems relating to a placenta are the most possible explanations about the noticed biochemical changings. Each of PAPP-A and free β-hCG is came into being in the placenta. High ST free β-hCG and low FT PAPP-A concentrations which are defined in usual conceived pregnancies with assistance are coherent with biochemical marker values stated at early pregnancy terms. A late development in placenta caused by the infertility (34) is because of the medicines which are taken to stimulate ovary (35). Laboratory based manipulations, or each of the factors (in this examination) may be reasonable causes for these changings. Being infertile itself or its level may be straight connected with these outcomes. Actually, Ranta et al. (34) observed that PAPP-A amounts were meaningfully decreased in natural conception pregnancies after some while to pregnancy more than two years compared with these conceived after a shorter while. Thisshows that infertility itself could be responsible for these biochemical changes. With the interpretation of the datas declared in singleton pregnancies obtained by ART, the higher the numbers of extra damaging factors in ART, the greater the retardation of development duration in the placenta and the higher the decrease of PAPP-A amounts.

**Conclusion**

Consequently, some researches have put forward that low FT PAPP-A concentrations may be the sign of hazard of pregnancy problems (38), in view of the increased perinatal morbidness observed in ART pregnancy (39). Nevertheless, Amor et al. (37), and Bender et al. (40), when complicated pregnancies were excluded, still observed meaningful decreases in PAPP-A amounts in ART pregnancies compared with natural conception pregnancies. Thus IVF pregnancies show PAPP-A decreases even in the lack of pregnancy complications.
Mentioned differentiations in the FT serum marker amounts may be accountable for increased incorrect positive outcomes causing to growing needless sprawling processes or supplementary requirement for further usage of cell-free fetal DNA test. The usage of ovarian stimulation in a controlled way preceding IVF is advised to be the basic cause for these changings of biomarkers in ART pregnancy.

**Ethics Committee Approval:** Ethics Committee of Göztepe Medical Park Hospital/Istanbul approved the study.

**Informed Consent:** Informed consent was not received on account of the retrospective content of the study.

**Conflict of interest:** Writers was not notified any conflict of interest.

**Financial Disclosure:** The writers notified that this study has not got any financial support.

**REFERENCES:**

1. Mangalraj AM, Muthukumar K, Aleyamma T, Kamath MS, George K. Blastocyst stage transfer vs cleavage stage embryo transfer. J Hum Reprod Sci 2009;2:23–6.

2. Karaki RZ, Samarraie SS, Younis NA, Lahloub TM, Ibrahim MH. Blastocyst culture and transfer: a step toward improved in vitro fertilization outcome. Fertil Steril 2002;77:114-18.

3. Edwards RG, Beard HK. Blastocyst stage transfer: pitfalls and benefits. Hum Reprod. 1999;14:1–4.

4. Gardner DK, Lane M. Culture and selection of viable blastocysts: a feasible proposition for human IVF? Hum Reprod Update. 1997;3:367–82.

5. Pool TB, Atiee SR, Martin JE. Oocyte and embryo culture: basic concepts and recent advances. Infert Reprod Med Clinics N Amer. 1998;9:181–203.

6. Tsirigotis M. Blastocyst stage transfer: pitfalls and benefits. Too soon to abandon current practice? Hum Reprod. 1998;13:3285–89.

7. Gardner DK, Schoolcraft WB. No longer neglected: the human blastocyst. Hum Reprod. 1998;13:3289–92.

8. Gardner DK, Balaban B. Choosing between day 3 and day 5 embryo transfers. Clin Obstet Gynecol. 2006;49:85–92.
9. Nicolaides KH. Screening for chromosomal defects. Ultrasound Obstet Gynecol. 2003;21:313–21.

10. Royal Australian and New Zealand College of Obstetricians and Gynaecologists and Human Genetics Society of Australasia. Prenatal screening tests for trisomy 21 (Down syndrome), trisomy 18 (Edwards syndrome) and neural tube defects. Victoria: Royal Australian and New Zealand College of Obstetricians and Gynaecologists; 2007.

11. Nicolaides KH. A model for a new pyramid of prenatal care based on the 11 to 13 weeks’ assessment. Prenat Diagn 2011; 31: 3-6.

12. Sonek J, Nicolaides KH. Additional first-trimester ultrasound markers. Clin Lab Med 2010; 30: 573-92.

13. Kagan KO, Wright D, Spencer K et al. First-trimester screening for trisomy 21 by free beta-human chorionic gonadotropin and pregnancy-associated plasma protein-A: impact of maternal and pregnancy characteristics. Ultrasound Obstet Gynecol 2008; 31: 493-502.

14. Chitayat DS, Langlois S, Wilson RD. Prenatal screening for fetal aneuploidy in singleton pregnancies. J Obstet Gynaecol Can 2011;33:736-50.

15. Spencer K, Staboulidou I, Nicolaides KH. First trimester aneuploidy screening in the presence of a vanishing twin: implications for maternal serum markers. Prenat Diagn 2010; 30: 235-40.

16. Klemetti R, Gissler M, Hemminki E. Comparison of perinatal health of children born from IVF in Finland in the early and late 1990s. Hum Reprod. 2002;17(8):2192–8.

17. Wright VC, Chang J, Jeng G, Macaluso M. Centers for disease C, prevention. Assisted reproductive technology surveillance—United States, 2005. MMWR Surveill Summ. 2008;57(5):1–23.

18. Chen H, Egan JO, Ohlu JF. Regulation and activities of alpha-fetoprotein, Crit Rev Eukaryot Gene Expr 1997; 7: 11-41.

19. Frendo JL, Vidaud M, Guibourdenche J, Luton D, Muller F, Bellet D, et al. Defect of villous cytotrophoblast differentiation into syncytiotrophoblast in Down's syndrome, J Clin Endocrinol Metab 2000; 85: 3700-07.

20. Krantz DA, Larsen JW, Buchanan PD, Macri JN. First-trimester Down syndrome screening: free beta-human chorionic gonadotropin and pregnancy-associated plasma protein A, Am J Obstet Gynecol 1996;174: 612-16.

21. Spencer K. Evaluation of an assay of the free beta-subunit of choriongonadotropin andits potential value in screening for Down's syndrome. Clin Chem 1991;37:809-14.

22. Almog B, Al-Shalaty J, Sheizaf B, Shehata F, Son WY, Tan SL, et al. Difference between serum beta-human chorionic gonadotropin levels in pregnancies after in vitro maturation and in vitro fertilization treatments. Fertil Steril 2011; 95: 85-8.

23. Cole LA. Immunoassay of human gonadotropin, its free subunits, and metabolites, Clin Chem 1997;43:2233-43.

24. Spencer K. Second-trimester prenatal screening for Down syndrome and the relationship of maternal serum biochemical markers to pregnancy complications with adverse outcome. Prenat Diagn 2000;20:652-56.

25. Dugoff L, Hobbins JC, Malone FD, Vidaver J, Sullivan L, Canick JA, et al. Quad screen as a predictor of adverse pregnancy outcome. Obstet Gynecol 2005;106:260-67.

26. Spencer K, Crossley JA, Aitken DA, Nix AB, Dunstan FD, Williams K. The effect of temporal variation in biochemical markers of trisomy 21 across the first and second trimesters of pregnancy on the estimation
of individual patient-specific risks and detection rates for Down's syndrome. Ann Clin Biochem 2003;40:219-31.

27. Zegers-Hochschild F, Altieri E, Fabres C, Fernandez E, Mackenna A, Orihuela P. Predictive value of human chorionic gonadotrophin in the outcome of early pregnancy after in-vitro fertilization and spontaneous conception. Hum Reprod 1994;9:1550-55.

28. Barkai G, Goldman B, Ries L, Chaki R, Dor J, Cuckle H. Down's syndrome screening marker levels following assisted reproduction Prenat Diagn 1996;16: 1111-14.

29. Wald NJ, White N, Morris JK, Hurtly WJ, Canick JA. Serum markers for Down’s syndrome in women who have had in vitro fertilisation: implications for antenatal screening. Br J Obstet Gynaecol 1999;106:1304-06.

30. Bar-Hava I, Yitzhak M, Kriissi H, Shohat M, Shalev J, Czitron B, et al. Triple-test screening in in vitro fertilization pregnancies. J Assist Reprod Genet 2001;18:226-9.

31. Giudice LC, Conover CA, Bale L, Faessen GH, Ilg K, Sun I, et al. Identification and regulation of the IGFBP-4 protease and its physiological inhibitor in human trophoblasts and endometrial stroma: evidence for paracrine regulation of IGF-II bioavailability in the placental bed during human implantation. J Clin Endocrinol Metab 2002;87:2359-66.

32. Santolaya-Forgas J, De Leon JA, Cullen HR, Castracane VD, Kauffman RP, Sifuentes GA. Low pregnancy-associated plasma protein-a at 10(+1) to 14(+6) weeks of gestation and a possible mechanism leading to miscarriage. Fetal Diagn Ther 2004;19:456-61.

33. Dumoulin JC, Land JA, Van Montfoort AP, Nelissen EC, Coonen E, Derhaag JG, et al. Effect of in vitro culture of human embryos on birthweight of newborns. Hum Reprod 2010;25:605-12.

34. Ranta JK, Raatikainen K, Romppanen J, Pulkki K, Heinonen S. Increased time-to-pregnancy and first trimester Down’s syndrome screening. Hum Reprod 2010;25:412–7.

35. Amor DJ, Xu JX, Halliday JL, Francis I, Healy DL, Breheny S, et al. Pregnanies conceived using assisted reproductive technologies (ART) have low levels of pregnancy-associated plasma protein-A (PAPP-A) leading to a high rate of false-positive results in first trimester screening for Down syndrome. Hum Reprod 2009;24:1330–8.

36. Anderson UD, Olsson MG, Kristensen KH, Akerström B, Hansson SR. Review: biochemical markers to predict preeclampsia. Placenta 2012;33:42–7.

37. Talaulikar VS, Arulkumaran S. Reproductive outcomes after assisted conception. Obstet Gynecol Surgy 2012;67:566–83.

38. Bender F, Hecken J, Reinsberg J, Berg C, Van der Ven H, Gembruch U, et al. Altered first-trimester screening markers after IVF/ICSI: no relationship with small-for-gestational-age and number of embryos transferred. Reprod Biomed Online 2010;20:516–22.